Avalo Therapeutics Inc [AVTX] stock is trading at $18.91, down -1.77%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AVTX shares have lost -3.08% over the last week, with a monthly amount glided 5.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avalo Therapeutics Inc [NASDAQ: AVTX] stock has seen the most recent analyst activity on December 18, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $39. Previously, H.C. Wainwright reaffirmed its Buy rating on September 17, 2025, and elevated its price target to $25. On September 05, 2025, TD Cowen initiated with a Buy rating. Cantor Fitzgerald started tracking the stock assigning a Overweight rating. Stifel started tracking with a Buy rating for this stock on March 25, 2025, and assigned it a price target of $36. In a note dated March 25, 2025, Jefferies initiated an Buy rating and provided a target price of $23 on this stock.
Avalo Therapeutics Inc [AVTX] stock has fluctuated between $3.39 and $20.72 over the past year. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Avalo Therapeutics Inc [NASDAQ: AVTX] shares were valued at $18.91 at the most recent close of the market. An investor can expect a potential return of 69.22% based on the average AVTX price forecast.
Analyzing the AVTX fundamentals
Avalo Therapeutics Inc [NASDAQ:AVTX] reported sales of 0.19M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at -0.15% with Operating Profit Margin at -346.32%, Pretax Profit Margin comes in at -519.42%, and Net Profit Margin reading is -520.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.8, Equity is -0.88 and Total Capital is -0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.43 points at the first support level, and at 17.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.75, and for the 2nd resistance point, it is at 20.60.
Ratios To Look Out For
For context, Avalo Therapeutics Inc’s Current Ratio is 14.28. Further, the Quick Ratio stands at 14.28, while the Cash Ratio is 3.38. Considering the valuation of this stock, the price to sales ratio is 1804.81, the price to book ratio is 3.68.
Transactions by insiders
Recent insider trading involved Goldman Jonathan, Director, that happened on Nov 14 ’25 when 11367.0 shares were sold.
